DDInter575 DDInter1676
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Disopyramide {u} (Compound) resembles {v} (Compound) Dextropropoxyphene
Disopyramide {u} (Compound) resembles {v} (Compound) Isopropamide
Disopyramide {u} (Compound) binds {v} (Gene) CHRM2
Disopyramide {u} (Compound) upregulates {v} (Gene) KIAA0355
Disopyramide {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Disopyramide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylprednisolone
Disopyramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Entrectinib
Disopyramide {u} may lead to a major life threatening interaction when taken with {v} Abarelix
Disopyramide (Compound) resembles Dextropropoxyphene (Compound)
Disopyramide (Compound) resembles Isopropamide (Compound)
Disopyramide (Compound) binds CHRM2 (Gene)
Disopyramide (Compound) upregulates KIAA0355 (Gene)
Disopyramide (Compound) causes Cardiac arrest (Side Effect)
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Insulin human
Disopyramide may lead to a major life threatening interaction when taken with Entrectinib
Disopyramide may lead to a major life threatening interaction when taken with Abarelix